Cyclosporin rapidly diminished a severe lupus-associated macrophage association syndrome refractory to pulsed methylprednisolone and intravenous immunoglobulin

Scandinavian Journal of Rheumatology

Volumn 38, Issue 6, 2009, Pages 492-494

  Takizawa, Y ^a   Maruyama, J ^a   Setoguchi, K ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOSPORIN; FERRITIN; HEMOGLOBIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; METHYLPREDNISOLONE; PREDNISOLONE; RO ANTIBODY; SM ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTHRITIS; CASE REPORT; COLD INJURY; COMPLEMENT HEMOLYSIS TEST; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; LACRIMATION; LETTER; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; PATHOPHYSIOLOGY; PERICARDITIS; PHOTOSENSITIVITY; PLEURISY; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; RASH; SALIVATION; SJOEGREN SYNDROME; SKIN DEFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIRHEUMATIC AGENTS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; METHYLPREDNISOLONE;

EID: 70450177484     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740902971221     Document Type: Letter

References (9)

1. Tristano A. Macrophage activation syndrome: A frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit 2008;/14:/RA27-36.
2. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;/48:/124-31.
3. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005;/7:/R30-7.
4. Kounami S, Yoshiyama M, Nakayama K, Okuda S, Aoyagi N, Yoshikawa N. Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol 2005;/113:/124-9.
5. Omagari K, Ashida R, Ohi H, Minamino Y, Sasaki O, Ozono Y, et al. Successful treatment with cyclosporine in a case of hemophagocytic syndrome manifesting as severe liver dysfunction. Am J Med Sci 1997;/314:/403-7.
6. Dhote R, Simon J, Papo T, Detournay B, Sailler L, Andre MH, et al. Reactive hemophagocytic syndrome in adult systemic disease: Report of twenty-six cases and literature review. Arthritis Rheum 2003;/49:/633-9.
7. Noble S, Wagstaff A. Cyclosporin: A review of its pharmacology and clinical potential in the treatment of systemic lupus erythematosus. BioDrugs 1997;/7:/483-501.
8. Griffiths B. The treatment of lupus with cyclosporin A. Lupus 2001;/10:/165-70.
9. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. Pglycoprotein in autoimmune diseases. Autoimmunity Rev 2004;/3:/188-92.